Day 1- Wednesday September 10th - EST (Eastern Time, UTC-05:00
EVE16 (Engineered Valency-Enhanced CD16A) is an immunoactivating receptor whose stability, surface expression, and function are dependent on the signaling adaptor proteins CD3ζ and FCER1G. These adaptors are selectively expressed in T cells, NK cells, and monocytes, restricting EVE16 expression to these immune cell types.
Targeted LNP delivery of EVE16-encoding mRNA enables in vivo expression specifically in immune cells, allowing for high-precision immune cell engineering.
EVE16 simultaneously interacts with a target receptor and the Fc domain of monoclonal antibodies, enabling synergistic activity with therapeutic mAbs.
- Nikola Ivica - Head of Discovery, InnDura Therapeutics
Exploring the use of ligand-siRNA conjugates to selectively silence SLC proteins in kidney cells.
Application of this novel approach to improve patient outcomes of systemic disease
- Alfica Sehgal, PhD - Chief Scientific Officer, Judo Bio
Pioneering the use of CRISPR technologies to modulate long non-coding RNAs driving cancer progression
- Rory Johnson - Associate Professor, University College Dublin
Exploring a first-in-class USP6-based mRNA immunotherapy to upregulate immunostimulatory pathways associated with an anti-tumour immune response
- Randall Hyer - Chief Executive Officer, Merlin Biotech
- Richard Shen - Co-Founder, EndoTope Bio